Blueprint Medicines
BPMC
#2202
Rank
โ‚น754.28 B
Marketcap
โ‚น11,664
Share price
0.00%
Change (1 day)
47.02%
Change (1 year)

Revenue for Blueprint Medicines (BPMC)

Revenue in 2025 (TTM): โ‚น47.58 Billion

According to Blueprint Medicines 's latest financial reports the company's current revenue (TTM ) is โ‚น50.64 Billion. In 2024 the company made a revenue of โ‚น43.65 Billion an increase over the revenue in the year 2023 that were of โ‚น20.76 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Blueprint Medicines from 2015 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) โ‚น47.58 B9.02%
2024 โ‚น43.65 B110.25%
2023 โ‚น20.76 B22.96%
2022 โ‚น16.88 B25.97%
2021 โ‚น13.40 B-76.91%
2020 โ‚น58.04 B1123.88%
2019 โ‚น4.74 B52.36%
2018 โ‚น3.11 B127.55%
2017 โ‚น1.36 B-27.51%
2016 โ‚น1.88 B149.11%
2015 โ‚น0.75 B

Revenue for similar companies or competitors

Company Revenue Revenue differencediff. Country
Isoray
ISR
โ‚น0.80 B-98.40%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
โ‚น57.85 B 14.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Pacific Biosciences
PACB
โ‚น13.92 B-72.50%๐Ÿ‡บ๐Ÿ‡ธ USA
Acceleron Pharma
XLRN
โ‚น10.16 B-79.94%๐Ÿ‡บ๐Ÿ‡ธ USA